Published in Clin Cardiol on July 24, 2013
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest (2013) 2.42
Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol (2009) 2.16
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out. Am J Med (2012) 2.08
Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. Am Heart J (2013) 2.05
Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm (2006) 2.03
Ventricular repolarization components on the electrocardiogram: cellular basis and clinical significance. J Am Coll Cardiol (2003) 1.81
The diagnosis of cardiac arrhythmias: a prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring. J Cardiovasc Electrophysiol (2007) 1.77
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J (2011) 1.72
Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J (2009) 1.66
L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation. J Cardiovasc Electrophysiol (2006) 1.57
Phase 2 reentry as a trigger to initiate ventricular fibrillation during early acute myocardial ischemia. Circulation (2004) 1.57
L-type calcium current recovery versus ventricular repolarization: preserved membrane-stabilizing mechanism for different QT intervals across species. Heart Rhythm (2007) 1.48
Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: a blinded validation. Heart Rhythm (2012) 1.44
Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy. Circ Arrhythm Electrophysiol (2009) 1.43
The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol (2009) 1.21
Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist (2013) 1.19
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc (2013) 1.15
Dronedarone. Circulation (2009) 1.14
Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry). Am J Cardiol (2010) 1.11
Electrical failure of an ICD lead due to a presumed insulation defect only diagnosed by a maximum output shock. Pacing Clin Electrophysiol (2013) 1.06
The QT and Tp-e intervals in left and right chest leads: comparison between patients with systemic and pulmonary hypertension. J Electrocardiol (2005) 1.06
ECG repolarization waves: their genesis and clinical implications. Ann Noninvasive Electrocardiol (2005) 1.02
Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J (2012) 1.01
Ventricular transmural repolarization sequence: its relationship with ventricular relaxation and role in ventricular diastolic function. Eur Heart J (2009) 0.99
First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. Am J Cardiol (2005) 0.99
Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes (2013) 0.97
Calcium-activated chloride current contributes to action potential alternations in left ventricular hypertrophy rabbit. Am J Physiol Heart Circ Physiol (2008) 0.96
Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol (2011) 0.96
A novel mutation in the KCNH2 gene associated with short QT syndrome. J Mol Cell Cardiol (2010) 0.94
Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol (2006) 0.94
Contribution of late sodium current (I(Na-L)) to rate adaptation of ventricular repolarization and reverse use-dependence of QT-prolonging agents. Heart Rhythm (2010) 0.92
PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects. Eur J Pharmacol (2009) 0.89
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol (2005) 0.88
Fast-track training of nonelectrophysiologists to implant defibrillators: is it needed? Pacing Clin Electrophysiol (2006) 0.87
Endothelial microparticles: sophisticated vesicles modulating vascular function. Vasc Med (2013) 0.87
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J (2013) 0.86
Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. Am J Med (2013) 0.86
Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J (2009) 0.86
Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol (2008) 0.85
Increasing I(Ks) corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy. Am J Physiol Heart Circ Physiol (2002) 0.83
The electrocardiographic manifestations of arrhythmogenic right ventricular dysplasia. Curr Cardiol Rev (2014) 0.83
Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J Cardiovasc Electrophysiol (2005) 0.82
Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans. Clin Exp Pharmacol Physiol (2012) 0.81
The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis (2004) 0.81
Increased late sodium current in left atrial myocytes of rabbits with left ventricular hypertrophy: its role in the genesis of atrial arrhythmias. Am J Physiol Heart Circ Physiol (2010) 0.80
Bioequivalence of 2 intravenous amiodarone formulations in healthy participants. J Clin Pharmacol (2009) 0.80
Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogs. Cardiovasc Toxicol (2009) 0.80
Case of polymorphic ventricular tachycardia in diphenhydramine poisoning. J Cardiovasc Electrophysiol (2004) 0.80
Proarrhythmias and antiarrhythmias: two sides of the same coin. Heart Rhythm (2005) 0.79
Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans. Am J Cardiol (2009) 0.79
Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies. Curr Opin Cardiol (2006) 0.78
Stroke prevention in atrial fibrillation. J Cardiovasc Med (Hagerstown) (2012) 0.78
Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol (2003) 0.77
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? Am J Cardiol (2008) 0.77
Drug therapy for atrial fibrillation. Med Clin North Am (2008) 0.76
Atrial fibrillation: pharmacological therapy. Curr Probl Cardiol (2011) 0.76
Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm (2011) 0.76
Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter. J Cardiovasc Electrophysiol (2011) 0.76
Future directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol (2006) 0.75
Born to be bradycardic? Cardiology (2010) 0.75
Discarding the baby with the bathwater. Pacing Clin Electrophysiol (2007) 0.75
You only get so many heartbeats... J Am Coll Cardiol (2004) 0.75
Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation. J Cardiovasc Electrophysiol (2007) 0.75
The meta-analysis: supportive or illuminating? Eur Heart J (2006) 0.75
Thoroughly measuring the QT interval: can we find the shortcuts? Heart Rhythm (2011) 0.75
"Doctor, why didn't you tell me about this before the ICD?". J Cardiovasc Electrophysiol (2006) 0.75
Drug-induced long-QT syndrome and torsade de pointes: an underrated problem? Europace (2013) 0.75
Response to Pasquale Santangeli, MD, Luigi Di Biase, MD, PhD, Andrea Natale, MD. Circ Arrhythm Electrophysiol (2014) 0.75
In reply. Oncologist (2014) 0.75
What's a mother to do? J Cardiovasc Electrophysiol (2011) 0.75
Boldly monitoring where few people have monitored before. Cardiology (2008) 0.75
The reply. Am J Med (2013) 0.75
Making a silk purse out of a sow's ear. J Am Coll Cardiol (2005) 0.75
Pharmacologic therapies for atrial fibrillation. Am J Geriatr Cardiol (2005) 0.75
Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis. J Cardiovasc Electrophysiol (2014) 0.75
Role of antiarrhythmic drugs: frequent implantable cardioverter-defibrillator shocks, risk of proarrhythmia, and new drug therapy. Heart Fail Clin (2011) 0.75
Ischemia versus amiodarone induced polymorphic ventricular tachycardia. Pacing Clin Electrophysiol (2002) 0.75
The geriatric paradox. Am J Geriatr Cardiol (2008) 0.75
Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. Clin Cardiol (2014) 0.75
Antiarrhythmic drug therapy. Curr Treat Options Cardiovasc Med (2006) 0.75
Reversal of fortunes: recognizing misplacement of ECG electrodes. Am J Med (2013) 0.75
Adjuvant therapy for atrial fibrillation. Future Cardiol (2010) 0.75
Evaluation of toxicity for heart failure therapeutics: studying effects on the QT interval. Circ Heart Fail (2010) 0.75
The unnecessary pacemaker controversy revisited. Pacing Clin Electrophysiol (2002) 0.75
A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. J Clin Pharmacol (2004) 0.75
Practical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants. Cardiology (2016) 0.75
Real-world algorithms for the optimal use of drugs and devices in the patient post myocardial infarction and the future of post myocardial infarction management. Clin Cardiol (2005) 0.75
Drug therapy for atrial fibrillation. Cardiol Clin (2009) 0.75
Why did you order that echocardiogram? Clin Cardiol (2010) 0.75